China Universal Asset Management Co. Ltd. Purchases 7,960 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

China Universal Asset Management Co. Ltd. grew its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 81.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,726 shares of the biopharmaceutical company’s stock after acquiring an additional 7,960 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $985,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of RARE. Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $28,000. nVerses Capital LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $33,000. UMB Bank n.a. raised its holdings in shares of Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 352 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth $56,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Ultragenyx Pharmaceutical by 67.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 1,339 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 22nd. Finally, TD Cowen raised their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.08.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $52.80 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $32.77 and a 1-year high of $60.37. The business has a fifty day moving average price of $56.03 and a 200-day moving average price of $47.75. The company has a market capitalization of $4.39 billion, a PE ratio of -6.60 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm had revenue of $147.03 million during the quarter, compared to the consensus estimate of $123.20 million. During the same period last year, the company earned ($2.25) earnings per share. The company’s revenue was up 35.7% on a year-over-year basis. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,243,985 shares in the company, valued at approximately $112,580,727.45. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $50.17, for a total value of $1,003,400.00. Following the transaction, the chief executive officer now directly owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,556 shares of company stock worth $2,519,367 over the last three months. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.